

2/28/24

Illinois State Legislature
Illinois Health Care Availability & Accessibility Committee
309 State Capitol Building
Springfield, IL 62706

Dear Members of the Health Care Availability & Accessibility Committee:

I am writing on behalf of the Alliance for Pharmacy Compounding to express opposition to HB5517, Health Care Costs Act. This bill places an unjustified burden on 503A compounding pharmacies and 503B outsourcing facilities in the state and fails to address the intended goal of reducing healthcare costs through its proposed requirements.

IL HB5517 includes 503A compounding pharmacies and 503B outsourcing facilities in its definition of “pharmaceutical manufacturer,” therefore requiring them to register as a pharmaceutical marketing firm and provide a list all employees who are sales representatives. This is an invasion of privacy, imposes an unnecessary hardship to pharmacies and outsourcing facilities, and will not decrease the cost of medications dispensed by pharmacies or outsourcing facilities one iota.

Furthermore, beyond the invasion of privacy and added burdensome administrative tasks, HB5517 fails to address several critical considerations:

- **Lack of Evidence for Cost Reduction:** The bill lacks evidence or analysis demonstrating how its requirements would lead to decreased healthcare costs. Without concrete data supporting the effectiveness of these measures, it is unwarranted to impose such mandates on pharmacies and outsourcing facilities.
- **Potential Negative Impact on Access to Medications:** The additional administrative burdens imposed on small-business pharmacies by HB5517 could divert resources away from patient care and essential pharmacy services, potentially affecting access to medications for patients across the state.
- **Disproportionate Impact on Small-Business Pharmacies:** Compliance with the requirements of HB5517 may disproportionately affect smaller 503A pharmacies and 503B outsourcing facilities, potentially leading to operational challenges or even closure, which could further limit patient access to essential medications.

For these reasons, we urge you to reject HB5517.

Thank you for this opportunity to comment on this bill. Please direct any questions to me at scott@a4pc.org.

Best,



Scott Brunner, CAE
Chief Executive Officer

The Alliance for Pharmacy Compounding is the voice for pharmacy compounding, representing more than 500 compounding small businesses – including compounding pharmacists and technicians in both 503A and 503B settings – as well as prescribers, educators, researchers, and suppliers.